Navigation Links
Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment
Date:11/14/2013

CARLSBAD, Calif. and UTRECHT, The Netherlands Nov. 12, 2013 One of the most comprehensive studies of genetic mutations in ovarian cancer was published today, demonstrating an unprecedented level of genetic variation that exists in both primary tumors and metastatic lesions of ovarian cancer. The study highlights potential new pathways for therapeutic intervention and suggests that sampling and sequencing of multiple disease sites may be required for effective targeted treatments.

The paper, titled "Genomic and transcriptomic plasticity in treatment-nave ovarian cancer," is available online at the journal Genome Research and is authored by scientists at the University Medical Center Utrecht in The Netherlands and Life Technologies Corporation in Carlsbad, Calif. With an annual global incidence of 220,000 and mortality of 140,0001, ovarian cancer is a leading cause of cancer deaths in women, making it a disease in urgent need of improved treatment.

The researchers examined a total of 27 archived tumor biopsy samples, both from primary tumors as well as distant metastatic sites, gathered from three women with late stage (IIIC/IV) ovarian cancer. Tumor samples and matched normal tissue samples were analyzed using a variety of methods, including transcriptome and mate-pair sequencing and several targeted gene sequencing panels. Sequencing was conducted on the Applied Biosystems SOLiD 5500xL and Ion Personal Genome Machine (PGM), both from Life Technologies, using Life's Ion AmpliSeq Comprehensive Cancer Panel, a panel of more than 400 genes that have been implicated in cancer. This study represents the first peer-reviewed, scientific publication employing this panel of 409 oncogenes.

The sequencing data revealed a striking degree of genetic heterogeneity within each individual's cancer. This was evident from profiles of coding mutations, genomic structural variation and gene expression changes. Of note, one of the individuals displayed
'/>"/>

Contact: Suzanne Clancy
Suzanne.Clancy@lifetech.com
760-602-4545
Life Technologies
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Elseviers Biochimica et Biophysica Acta (BBA) journal series adds open access journal: BBA Clinical
2. Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
3. Development and clinical approval of biodegradeble magnesium alloy
4. Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing
5. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
6. Breastfeeding as a possible deterrent to autism -- a clinical perspective
7. Projecis Cloud-based Collaboration Platform Selected by Spaulding Clinical to Manage Phase I Clinical Trial Projects and Timelines
8. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
9. Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support
10. UNLV, Sen. Reid Announce $20 Million NIH grant to support clinical health research
11. Wistar receives $1.5 million Department of Defense grant to ready prostate drug for clinical use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), a leading developer ... report financial results for the fourth quarter and fiscal ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-455-2260 (conference ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
(Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
... Soil Use and Management attempts for the first time ... globe and concludes that 24% of the land area is degrading ... decline in the quality of soil, water and vegetation is ... global data by which to assess its extent and severity. For ...
... 20, 2009 Ecopsychologyan emerging field that explores the ... in which ecology and psychology interact on individual, societal, ... peer-reviewed journal, Ecopsychology to be launched by ... ). Ecopsychology will explore the relationship ...
... good gumshoe. The University of Alberta medical geneticist has cracked ... Glaucoma is a leading cause of blindness in which cells ... what patients see. Scientists have long suspected a link between ... what the gene does and why some people with variations ...
Cached Biology News:A quarter of the world's population depends on degrading land 2New ecopsychology journal will premiere in spring 2009 2Genetic sleuth solves glaucoma mystery 2
(Date:7/23/2015)... ... July 23, 2015 , ... July ... by providing more targeted treatment options with fewer side effects, according to Erik ... Anderson Cancer Center. , At the American Brain Tumor Association (ABTA) National Patient ...
(Date:7/23/2015)... , July 23, 2015 /PRNewswire/ - Portage Biotech Inc. ... and Biohaven Pharmaceutical Holding Company Limited (Biohaven), are ... Investigational New Drug (IND) Application with the U.S. ... testing of BHV-0223. Portage holds 54% equity interest ... is a glutamate modulating agent and Biohaven has ...
(Date:7/23/2015)... 2015 OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... invites investors and the general public to its Annual ... Friday, July 31, 2015. The meeting will be held ... San Diego, California 92121.   ... also be available. Please use the following link to ...
(Date:7/23/2015)... , ... July 23, 2015 , ... Global Stem ... research in Santiago, Chile. The symposium will feature some of the world’s most ... day of high-level scientific discussion for medical professionals in general practice. , The ...
Breaking Biology Technology:Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4OncoSec to Webcast Annual Meeting of Stockholders 2Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 2Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 3
... Although the <A , href="http://www.ambion.com/catalog/CatNum.php?1632"> Silencer ... for labeling siRNA, they can , be ... can be used for this application. See "<A , ... Introduced dsRNA in Cells " for experimintal data using dsRNA , ...
... , RNA later is a tissue storage , ... fresh , tissues. (Ambion's ... specifically for use with frozen tissues - see "<A , ... Grinding Frozen Tissue " for more information.) Tissue , ...
... NAVIGATE THIS ARTICLE: <A , href="#1">What , ... href="#2">Advantages , > <A , ... , href="#4">Steps , , ... a Nuclease Protection , Assay? , ...
Cached Biology Technology:Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 2Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 3Fluorescently Labeling Long dsRNA with the Silencer siRNA Labeling Kit 4RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 2RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 3RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 4RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 5RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 6RNArticles: Keeping RNA Intact Prior to RNA Isolation - RNAlater 7Nuclease Protection Assays: The Basics 2Nuclease Protection Assays: The Basics 3Nuclease Protection Assays: The Basics 4Nuclease Protection Assays: The Basics 5Nuclease Protection Assays: The Basics 6Nuclease Protection Assays: The Basics 7Nuclease Protection Assays: The Basics 8Nuclease Protection Assays: The Basics 9Nuclease Protection Assays: The Basics 10
... Loading Buffer contains a precipitant to ensure that ... tracking dye to allow the user to follow ... ReddyRun™: ABgene ® s proprietary mixture ... same buffer composition used in ReddyRun™ molecular weight ...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,381-3) or contact ...
Excellent safety and durability., Remote control can be easily operated in your hand., Constant voltage control with 2 sets of terminals., Precise and durable circuit design. ...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
Biology Products: